Big Pharma's Big Plans for New Fish Oil Drug

Big Pharma's Big Plans for New Fish Oil Drug

This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines, highlighting the stories and stocks that should be on all investors' radars. Market Checkup gives a full examination of the recent regulatory action around a new super fish-oil drug and looks at a yet another biotech putting itself up for sale.

In this video, health-care analysts David Williamson and Max Macaluso discuss the FDA's accepting a new drug application for Epanova. AstraZeneca recently spent more than $400 million acquiring the rights to the fish oil-based drug and has big plans for it. Watch and find out about Epanova's competitors, why recent studies may work against it, and what AstraZeneca has up its sleeve that makes this drug so important to the big pharma.

Prescription for dividends
One of the best parts of owning Big Pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Follow David on Twitter: @MotleyDavid.

The article Big Pharma's Big Plans for New Fish Oil Drug originally appeared on

David Williamson owns shares of Amarin. Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.